List of Excipients in Branded Drug YERVOY

YERVOY Excipient Strategy and Commercial Opportunities for Ipilimumab

Last updated: August 21, 2026

YERVOY is an intravenous ipilimumab solution containing a deliberately simple excipient system: diethylenetriaminepentaacetic acid, polysorbate 80, sodium chloride, tromethamine hydrochloride, and water for injection. The commercial opportunity is concentrated in high-purity excipient supply, antibody-stability services, biosimilar formulation development, combination-product manufacturing, and alternatives to conventional polysorbate-based formulations. YERVOY is a biologic, so its regulatory exclusivity and patent analysis runs through the FDA Purple Book and BLA-related intellectual-property framework rather than the small-molecule Orange Book.

What excipients are used in YERVOY?

YERVOY contains five inactive ingredients in its marketed U.S. formulation.

Component	Approximate concentration per mL	Primary formulation role
Diethylenetriaminepentaacetic acid, or DTPA	0.04 mg	Chelates trace metals and limits metal-catalyzed degradation
Polysorbate 80	0.1 mg	Reduces interfacial adsorption and aggregation
Sodium chloride	5.84 mg	Controls tonicity
Tromethamine hydrochloride	3.15 mg	Provides buffering capacity
Water for injection	q.s.	Injectable vehicle

The product is supplied as a 5 mg/mL intravenous solution in single-dose 10 mL and 40 mL vials, corresponding to 50 mg and 200 mg of ipilimumab, respectively. The formulation does not use a lyophilized presentation or a proprietary delivery device in the U.S. label (Bristol Myers Squibb, 2024).

Why does YERVOY use polysorbate 80?

Polysorbate 80 protects the monoclonal antibody from adsorption to vial surfaces, infusion containers, tubing, and air-liquid interfaces. These stress points can cause aggregation or particle formation during storage, handling, dilution, and administration.

For suppliers, the commercial value lies less in bulk polysorbate volume than in consistency across:

• Peroxide and aldehyde impurity profiles
• Hydrolysis and oxidation behavior
• Subvisible-particle performance
• Lot-to-lot variability
• Compatibility with stainless steel, single-use systems, and infusion bags

Polysorbate 80 is widely used and generally not a meaningful standalone exclusivity barrier. Its importance is technical and quality-related. A supplier that can provide low-variability, low-peroxide material with strong extractables, leachables, and stability data has a stronger position than a commodity supplier.

What is the role of DTPA in ipilimumab stability?

DTPA is a chelating agent. It binds trace metal ions that can catalyze oxidation of proteins and excipients. In an antibody formulation, DTPA can reduce the impact of metal contamination introduced through raw materials, processing equipment, containers, or dilution systems.

DTPA creates a specialized supply opportunity because injectable use requires control of:

• Identity and assay
• Metal content
• Endotoxin
• Bioburden
• Particulate matter
• Residual solvents
• Container-closure compatibility

DTPA is a smaller-volume excipient than sodium chloride or polysorbate 80, but it can have higher strategic value because the formulation depends on its impurity and chelation profile.

How does the YERVOY formulation support commercial manufacturing?

YERVOY is a ready-to-dilute liquid monoclonal antibody product. The formulation avoids the additional manufacturing steps required for lyophilized products, including freeze-drying, cake development, reconstitution validation, and longer preparation procedures.

The commercial advantages include:

1. A conventional sterile-liquid fill-finish process.
2. A limited number of excipients.
3. A standard intravenous infusion route.
4. No device-specific delivery platform.
5. Compatibility with dilution before administration under labeled conditions.

The technical tradeoff is that liquid antibodies can be more vulnerable to aggregation, oxidation, deamidation, adsorption, and particle formation than some lyophilized products. The excipient system therefore depends on tight control of pH, ionic strength, metal contamination, agitation, temperature, and container-closure materials.

What manufacturing barriers affect YERVOY excipient supply?

The main barriers are qualification and comparability rather than exclusivity. A new excipient supplier must demonstrate that its material does not alter:

• High-molecular-weight species
• Charge variants
• Potency
• Binding activity
• Subvisible particles
• Visible particles
• Protein concentration
• pH and osmolality
• Sterility assurance
• Stability during dilution and infusion

A change in polysorbate 80, DTPA, tromethamine hydrochloride, or sodium chloride may require extensive comparability work. For a licensed biologic, the sponsor must assess the change under its pharmaceutical quality system and applicable FDA postapproval-change requirements. A supplier with a robust change-notification program can be more valuable than one offering a lower nominal price.

What commercial opportunities exist around YERVOY excipients?

The strongest opportunities are in specialized inputs and services that reduce formulation risk.

High-purity polysorbate 80

Suppliers can differentiate through:

• Low-peroxide grades
• Controlled fatty-acid composition
• Defined hydrolysis profiles
• Pharmaceutical-grade documentation
• Low particulate burden
• Long-term supply agreements
• Compatibility data for monoclonal antibodies

The market is competitive, but biologic manufacturers have strong incentives to avoid unplanned supplier changes. Once an excipient grade is qualified, switching costs can be substantial.

Pharmaceutical-grade DTPA

DTPA offers a more specialized opportunity because it is used at low concentration but performs a specific stabilization function. Suppliers can target antibody manufacturers that require:

• Trace-metal control
• Low-endotoxin material
• Sterile or low-bioburden supply
• GMP documentation
• Global regulatory support
• Consistent particle and solubility performance

Tromethamine and buffer systems

Tromethamine hydrochloride provides buffering capacity in the YERVOY formulation. Buffer suppliers can compete through validated pharmaceutical grades, global registrations, low extractables, and reliable supply during capacity constraints.

Alternative buffer systems may be relevant for biosimilar developers or next-generation ipilimumab products, but a change in buffer chemistry can affect protein charge, aggregation, viscosity, potency, and infusion tolerability.

Excipient characterization and analytical services

Contract laboratories can support YERVOY-related development through:

• Polysorbate degradation testing
• Peroxide and aldehyde analysis
• DTPA and trace-metal testing
• Protein aggregation assays
• Subvisible-particle testing
• Container-closure compatibility
• In-use and dilution stability
• Infusion-line adsorption studies
• Extractables and leachables programs

This service market can be more accessible than direct excipient supply because developers need independent analytical packages for biosimilars, process changes, and combination products.

What formulation opportunities exist for ipilimumab biosimilars?

A biosimilar developer does not necessarily need to duplicate every excipient at the same concentration, but it must establish that formulation differences do not affect safety, purity, potency, or clinical performance. The reference formulation provides a critical benchmark.

Potential biosimilar strategies include:

Strategy	Commercial benefit	Main technical risk
Match the reference excipient system	Reduces formulation comparability risk	May preserve dependence on polysorbate 80 and DTPA
Use an alternative surfactant	May improve oxidation or particle control	Requires extensive comparability evidence
Use a different buffer	May improve stability or manufacturing economics	Can change charge variants and potency
Develop a higher-concentration product	May reduce infusion volume	Increased viscosity, aggregation, and dosing risks
Develop a subcutaneous presentation	Could reduce administration burden	Requires new device, clinical, and regulatory work
Develop a co-formulation with another antibody	May simplify combination treatment	High compatibility and regulatory complexity

The most practical biosimilar opportunity is generally a reference-like intravenous product. A materially different formulation may create a differentiated product, but it increases development cost and regulatory risk.

When does YERVOY lose exclusivity?

YERVOY’s U.S. biologic exclusivity period began with FDA approval of BLA 125377 in March 2011. The statutory 12-year reference-product exclusivity period for a biologic therefore expired in March 2023, subject to the precise statutory calculation and any pediatric-exclusivity adjustment. The product can be challenged through the abbreviated biosimilar pathway after reference-product exclusivity ends, although commercial launch also depends on patents, litigation, regulatory approval, and manufacturing readiness (FDA, 2024a).

YERVOY is not a conventional small-molecule product listed in the Orange Book. Biologic reference products and biosimilar competition are tracked through the Purple Book. The absence of Orange Book listings does not mean the product lacks patent protection.

What patents protect YERVOY?

YERVOY may be covered by several categories of intellectual property:

• Antibodies that bind CTLA-4
• Antibody sequences and variants
• Pharmaceutical compositions
• Manufacturing and purification processes
• Combination therapies with nivolumab or other agents
• Treatment methods and dosing regimens
• Formulations and stability improvements

The commercially relevant question is not only whether a patent exists, but whether it covers the product, a biosimilar’s manufacturing process, a specific formulation, or a method of treatment that a proposed entrant would practice.

Patent expiration must be evaluated patent by patent. Biological-product exclusivity, patent term, patent-term adjustment, patent-term extension, pediatric exclusivity, terminal disclaimers, and litigation settlements can produce different dates.

Are there YERVOY Paragraph IV challenges?

Paragraph IV certifications apply to patents listed in the Orange Book for approved drug applications. YERVOY is a biologic reference product, so biosimilar applicants generally use the Biologics Price Competition and Innovation Act patent-exchange process rather than submitting a standard small-molecule Paragraph IV certification.

A biosimilar applicant may still challenge relevant patents, assert non-infringement, raise invalidity arguments, or negotiate a commercial-entry date. The dispute may involve:

• Composition claims
• Formulation claims
• Manufacturing claims
• Combination-treatment claims
• Dosing and administration claims

The absence of an Orange Book Paragraph IV filing is therefore not evidence that YERVOY has no competitive patent risk.

What FDA regulatory status affects YERVOY commercial opportunities?

FDA approved YERVOY in 2011 for unresectable or metastatic melanoma. The label has since expanded to include multiple oncology settings, often in combination with nivolumab or other therapies. These indications include renal cell carcinoma, colorectal cancer with specified molecular characteristics, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, esophageal cancer, and other tumor types depending on the current label (FDA, 2024b).

The broad indication base increases demand for:

• Infusion-center supply
• Standardized dilution systems
• Closed-system transfer devices
• Low-sorbing infusion bags and tubing
• Stability studies for combination regimens
• Biosimilar analytical comparability
• Combination-product manufacturing capacity

Combination use also increases the importance of administration sequence, dilution stability, infusion-line compatibility, and coadministration procedures.

How does YERVOY compare with OPDIVO from an excipient perspective?

YERVOY and OPDIVO are both Bristol Myers Squibb oncology biologics, but their active antibodies and formulation systems differ.

Attribute	YERVOY	OPDIVO
Active ingredient	Ipilimumab	Nivolumab
Target	CTLA-4	PD-1
Route	Intravenous infusion	Intravenous infusion; subcutaneous formulation also developed and approved in some markets
Marketed liquid strength	5 mg/mL	Product- and presentation-specific
Key excipient considerations	DTPA, polysorbate 80, sodium chloride, tromethamine hydrochloride	Surfactant, buffer, tonicity and formulation-specific stability
Combination role	Often paired with nivolumab	Often paired with ipilimumab
Main formulation opportunity	Biosimilar matching and infusion optimization	Higher-concentration and subcutaneous delivery innovation

OPDIVO has a broader platform opportunity because subcutaneous delivery can support device and formulation innovation. YERVOY’s more immediate opportunity is in reference-like biosimilar development, excipient supply, and combination-infusion infrastructure.

What generic and biosimilar launch risks exist for YERVOY?

YERVOY does not face ordinary generic substitution because ipilimumab is a monoclonal antibody. Competitive entry would most likely come from biosimilars or interchangeable biosimilars, subject to FDA approval and product-specific determinations.

Key launch risks include:

• Difficulty matching antibody quality attributes
• Manufacturing scale and yield
• Polysorbate degradation during shelf life
• Aggregation and particulate control
• Clinical immunogenicity
• Patent litigation
• Physician and payer adoption
• Hospital formulary contracting
• Combination-regimen economics
• Reference-product switching policies

Excipient strategy can reduce some development risk but cannot compensate for inadequate control of the antibody molecule, process-related impurities, or clinical comparability.

How strong is the YERVOY formulation patent estate?

The formulation estate should be assessed as part of a broader biologic patent portfolio rather than as a single excipient patent. The commercial strength of an excipient-related claim depends on whether it covers:

• The exact commercial concentration range
• A defined antibody and buffer combination
• A stability result that competitors cannot easily design around
• A manufacturing step required for the product
• A combination regimen with meaningful market share
• A formulation used in the approved product

DTPA, polysorbate 80, sodium chloride, and tromethamine hydrochloride are established pharmaceutical ingredients. Broad claims directed only to those excipients are likely to face substantial prior-art exposure. Narrow claims linking the excipients to ipilimumab stability, impurity control, or a specific manufacturing process may have greater practical relevance.

What licensing and partnership opportunities exist?

Potential counterparties include:

• Specialty excipient manufacturers
• Polysorbate producers
• DTPA suppliers
• Contract development and manufacturing organizations
• Biosimilar developers
• Infusion-system manufacturers
• Analytical testing laboratories
• Oncology-focused distributors

The most realistic deal structures are supply agreements, dual-source qualification programs, analytical-services contracts, and formulation-development collaborations. A license covering YERVOY’s basic excipients would be less likely to create material value because the ingredients are established and broadly available. Greater value may arise from proprietary low-peroxide surfactants, alternative stabilizers, high-concentration formulations, or delivery systems.

What is the geographic coverage of YERVOY excipient opportunities?

The core excipient strategy is global because the same biologic requires consistent supply across major markets. Commercial differences arise from:

• Regional pharmacopoeial standards
• Local GMP expectations
• Approved formulation differences
• Biosimilar approval pathways
• Patent-term differences
• Hospital procurement systems
• Cold-chain infrastructure
• Availability of sterile fill-finish capacity

The European Union and United States remain the highest-value markets for reference-product and biosimilar competition. Japan, Canada, South Korea, Australia, and emerging oncology markets provide additional opportunities for regional biosimilar supply and contract manufacturing.

Key Takeaways

• YERVOY uses DTPA, polysorbate 80, sodium chloride, tromethamine hydrochloride, and water for injection.
• The formulation’s main technical objectives are antibody stability, metal control, tonicity, buffering, and reduction of interfacial aggregation.
• The strongest excipient opportunities are low-variability polysorbate 80, pharmaceutical-grade DTPA, buffer supply, and analytical characterization.
• YERVOY’s biologic exclusivity period began in March 2011 and expired after the statutory 12-year period, subject to applicable exclusivity adjustments.
• Biosimilar competition is evaluated through the Purple Book and BPCIA framework, not a conventional Orange Book Paragraph IV process.
• The highest-value IP risks may involve formulation, manufacturing, combination, and method-of-treatment claims rather than the individual excipients.
• A reference-like intravenous biosimilar is the lowest-risk commercial pathway. Higher-concentration, subcutaneous, or co-formulated products offer greater differentiation but require materially more development work.

FAQs

Can polysorbate 80 be replaced in a YERVOY biosimilar?

Yes, a biosimilar developer may use another surfactant, but it must demonstrate comparable quality, stability, potency, safety, and immunogenicity performance. A reference-matched polysorbate 80 formulation is generally the lower-risk development strategy.

Is DTPA essential to ipilimumab activity?

DTPA is not the active ingredient and does not create the antibody’s pharmacologic activity. It can support formulation stability by binding trace metals and reducing metal-catalyzed degradation.

Could YERVOY be reformulated as a subcutaneous injection?

A subcutaneous ipilimumab product would require a new formulation and delivery strategy. Key barriers include injection volume, viscosity, concentration, local tolerability, device compatibility, immunogenicity, and clinical validation.

Do YERVOY excipients create a standalone patent barrier?

The individual excipients are established pharmaceutical ingredients. Any meaningful barrier is more likely to arise from claims linking those excipients to ipilimumab, a defined stability profile, manufacturing process, combination regimen, or approved use.

Which suppliers benefit most from YERVOY biosimilar competition?

Suppliers with validated low-peroxide polysorbate 80, high-purity DTPA, pharmaceutical-grade tromethamine, sterile liquid fill-finish capacity, and advanced protein-stability testing are best positioned to benefit from biosimilar development.

References

1. Bristol Myers Squibb. (2024). YERVOY (ipilimumab) injection, for intravenous use: U.S. prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024a). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

3. U.S. Food and Drug Administration. (2024b). YERVOY approval history and prescribing information. https://www.fda.gov/

4. U.S. Food and Drug Administration. (2023). Questions and answers on biosimilar development and the BPCI Act. https://www.fda.gov/

5. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

6. European Medicines Agency. (2024). YERVOY: Product information. https://www.ema.europa.eu/